Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Genestreti, Giovenzio; Tiseo, Marcello; Kenmotsu, Hirotsugu; Kazushige, Wakuda; Di Battista, Monica; Cavallo, Giovanna; Carloni, Federica; Bongiovanni, Alberto; Burgio, Marco; Casanova, Claudia; Metro, Giulio; Scarpi, Emanuela; Korkmaz, Taner; Selcuk, Seber; Roopa, Kurup; Califano, Raffaele

doi:10.1016/j.cllc.2015.04.006

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Atıf İçin Kopyala

Genestreti G., Tiseo M., Kenmotsu H., Kazushige W., Di Battista M., Cavallo G., ...Daha Fazla

CLINICAL LUNG CANCER, cilt.16, sa.6, 2015 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16 Sayı: 6
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.cllc.2015.04.006
Dergi Adı: CLINICAL LUNG CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Extended disease, Platinum sensitive, Rechallenge chemotherapy, SCLC, Second-line, 2ND-LINE TREATMENT, PHASE-III, CHEMOTHERAPY, TOPOTECAN, GUIDELINES, THERAPY, RELAPSE
Marmara Üniversitesi Adresli: Evet

Özet

Small-cell lung cancer has a high chemotherapeutic sensitivity but with disappointing outcome results. Patients with "sensitive disease" are those who respond to treatment with a long relapse-free interval (RFI): in these cases rechallenge with first-line chemotherapy might represent a therapeutic opportunity. Our largest retrospective experience confirmed that rechallenge is feasible with interesting outcome results; there are no statistical differences between RFI and outcome.